It Is Time to End the Dualistic Short Versus Long Duration of Dual Antiplatelet Therapy Debates

Circulation. 2017 Jun 20;135(25):2451-2453. doi: 10.1161/CIRCULATIONAHA.117.028497.

Authors

Glenn N Levine¹, Eric R Bates²

Affiliations

¹ From Baylor College of Medicine and Michael E. DeBakey VA Medical Center, Houston, TX (G.N.L.); and University of Michigan, Ann Arbor (E.R.B.). [email protected].
² From Baylor College of Medicine and Michael E. DeBakey VA Medical Center, Houston, TX (G.N.L.); and University of Michigan, Ann Arbor (E.R.B.).

PMID: 28630264
DOI: 10.1161/CIRCULATIONAHA.117.028497

No abstract available

Keywords: antiplatelet aggregation inhibitors.

MeSH terms

Acute Coronary Syndrome / drug therapy*
Graft Occlusion, Vascular / drug therapy*
Humans
Platelet Aggregation Inhibitors / administration & dosage*
Platelet Aggregation Inhibitors / adverse effects
Stents / adverse effects*
Thrombosis / drug therapy*
Thrombosis / etiology
Time Factors

Substances

Platelet Aggregation Inhibitors